With the acquisition of the Swedish company Key2Compliance AB, GBA Group is expanding its range of consulting and training services for the medical device, In Vitro Diagnostics (IVD), and pharmaceutical industry. GBA Group is thus taking another important step towards establishing itself as a broad service provider for international customers in this area.

On Sept. 26, 2023, Dr. Sabine Gorynia, EVP GBA Group Pharma & Medical Devices, Torben Giese, Chief Strategy Officer GBA Group, and Felix Bunde, Managing Director GBA MDS, visited the new colleagues at ICCR Roßdorf GmbH.

"Global efforts in the area of health care will continue to grow in the future. With this in mind, GBA Group has significantly expanded its Pharma & Medical Devices portfolio and will continue to invest in this growth market to position itself as a professionally comprehensive and internationally positioned laboratory and service provider for the benefit of our society." Steffen Walter, CEO.

GBA Group's new laboratory and logistics site in Westborough (MA) will support growing demand from international clients.

Located in the greater Boston area, a pharmaceutical and biotech hub, the laboratory and logistics site will be fully operational in October 2023 and will offer a broad range of services in the areas of central lab and clinical trial supply.

The FDA recently published an "Immediately in Effect Guidance for Industry" for testing diethylene glycol (DEG) and ethylene glycol (EG). According to FDA “this guidance is intended to alert pharmaceutical manufacturers, compounders, repackers, and suppliers to the potential public health hazard of glycerin and other high-risk drug components contaminated with DEG or EG”.

Examples of high-risk drug components under the following Link: